---
title: A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
nct_id: NCT06605703
overall_status: COMPLETED
phase: PHASE4
sponsor: WW International Inc
study_type: INTERVENTIONAL
primary_condition: Obesity
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06605703.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06605703"
ct_last_update_post_date: 2026-04-13
last_seen_at: "2026-05-12T06:16:14.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)

**Official Title:** The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: A Randomized Controlled Trial (GLP1 Transition Trial)

**NCT ID:** [NCT06605703](https://clinicaltrials.gov/study/NCT06605703)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 226
- **Lead Sponsor:** WW International Inc
- **Conditions:** Obesity, Overweight
- **Start Date:** 2024-09-18
- **Completion Date:** 2026-02-05
- **CT.gov Last Update:** 2026-04-13

## Brief Summary

The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years or older
* Previous hx of BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
* Currently taking Wegovy, Ozempic, Mounjaro or Zepbound and have been for at least 6 months
* At least 15% body weight loss since taking Wegovy, Ozempic, Mounjaro, or Zepbound
* Willing to stop taking their GLP-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason
* Ability to provide informed consent prior to any trial-related activities
* Able to read and write in English

Exclusion Criteria:

* BMI \<22 kg/m2
* Diabetes
* Previous surgical obesity treatment
* Currently pregnant or intending to become pregnant during the study
* Breastfeeding
* History of seizures or epilepsy
* Current opioid use or in acute opioid withdrawal
* Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs
* History of glaucoma
* Uncontrolled hypertension
* Severe renal impairment and/or Chronic kidney disease stage III or GFR \<60
* Acute hepatitis or liver failure
* Acute or chronic metabolic acidosis, including diabetic ketoacidosis
* Use of antipsychotic medications or opiod analgesics
* Current or previous history of anorexia or bulimia nervosa
* Engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight
* Current SSRI, SNRI, mood stabilizer, amphetamine, or corticosteroid use
* Current diagnosis of hyper or hypothyroidism or current use of thyroid replacement medicine
* Current use of beta blockers
* Current use of depo shot (medroxyprogesterone acetate) for birth control
* Current diagnosis of Cushing's disease or syndrome
* Current use of Monoamine Oxidase Inhibitors (MAOIs)
* Known hypersensitivity to bupropion, naltrexone, or metformin
* Any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator
```

## Arms

- **WW Clinic - No medications** (EXPERIMENTAL) — Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive no medications.
- **WW Clinic + Meds v1** (EXPERIMENTAL) — Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.
- **WW Clinic + Meds v2** (EXPERIMENTAL) — Participants in this group receive behavioral or lifestyle support from WW Clinic. They receive medications prescribed through WW Clinic.

## Interventions

- **WW Clinic** (BEHAVIORAL) — Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
- **Bupropion-Naltrexone** (DRUG) — Bupropion-Naltrexone
- **Bupropion-Naltrexone-Metformin** (DRUG) — Bupropion-Naltrexone-Metformin

## Primary Outcomes

- **Percent body weight change at 12 weeks** _(time frame: Baseline, 12 weeks)_ — Measurement of weight using a bluetooth body weight scale

## Secondary Outcomes

- **Change in body weight (in kg or pounds) at 12 weeks** _(time frame: Baseline, 12 weeks)_
- **Physical Activity and Sedentary Behavior** _(time frame: Baseline, 12 weeks)_
- **Dietary Intake** _(time frame: Baseline, 12 weeks)_
- **Habit/Automaticity** _(time frame: Baseline, 12 weeks)_
- **Hunger VAS (Visual Analogue Scale)** _(time frame: Baseline, 12 weeks)_
- **Impact on Quality of Life** _(time frame: Baseline, 12 weeks)_
- **Well-being** _(time frame: Baseline, 12 weeks)_
- **Body Appreciation** _(time frame: Baseline, 12 weeks)_
- **Self-Compassion** _(time frame: Baseline, 12 weeks)_
- **Weight Bias** _(time frame: Baseline, 12 weeks)_

## Locations (1)

- WW International, Inc, New York, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ww international, inc|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06605703.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06605703*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*